259184-49-1

Upstream product

• 128510-52-1 benzoic acid (S)-1-benzyl-pyrrolidin-3-yl ester 
• 132945-74-5 (S)-N-tert-butoxycarbonylpyrrolidin-3-yl benzoate 
• 65-85-0 benzoic acid 

Downstream Products

• 479687-09-7 Benzoic acid (S)-1-((S)-2-tert-butoxycarbonylamino-2-phenyl-acetyl)-pyrrolidin-3-yl ester 
• 99395-88-7 (S)-4-phenyl-2-oxazolidinone 
• 479687-34-8 Benzoic acid (S)-1-((S)-2-amino-2-phenyl-ethyl)-pyrrolidin-3-yl ester 
• 479687-32-6 Benzoic acid (S)-1-((S)-2-benzyloxycarbonylamino-2-phenyl-ethyl)-pyrrolidin-3-yl ester 
• 479687-38-2 Benzoic acid (S)-1-[(S)-2-phenyl-2-(4-propylcarbamoyl-phenylamino)-ethyl]-pyrrolidin-3-yl ester 
• 473916-34-6 (2'S,3S)-3-benzoyloxy-N-{2-[N-methyl-N-4-(N-propylaminocarbonyl)phenyl]amino-2-phenyl}ethylpyrrolidine 
• 259184-51-5 (2'S,3S)-3-benzoyloxy-N-(2-hydroxy-2-phenylethyl)pyrrolidine 

Relevant academic research and scientific papers

PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES

A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.